Featured ArticlesGlobal Health

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

By March 30, 2020April 29th, 2020No Comments

Dermatology News

Featured Article

Dermatologist looking at skin

"Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?"

While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.

Immunosuppressive drugs are used ubiquitously in the modern treatment of inflammatory and autoimmune skin diseases like psoriasis, bullous diseases, connective tissue diseases, and many others. Treatment of these conditions is based on the suppression of the patient’s immune system using steroids, steroid-sparing drugs, and biological agents.1
“The use of immunosuppressive to treat these conditions can amplify this effect, and it might leave the patient vulnerable to more serious complications should an infection with the novel coronavirus be established. Hence, it may be wise to restrict temporarily the use of immunosuppressive agents including systemic steroids, steroid-sparing agents, and biologics in dermatology daily practice until more evidence is avilable about their safety in the current pandemic.6 As a relates point, the International Psoriasis Council declared an urgent statement on March 11, 2020 that the physician should be alert to the potentially harmful effects of COVID-19 infection on patients with psoriasis and to immediately discontinue or postpone immunosuppressant medications for psoriasis patients diagnosed with COVID-19 disease.”

As the declaration of the novel coronavirus as a pandemic by the WHO is a trending topic nowadays, dermatologists around the world view with concern the impact of this pandemic on their daily practice.

Read Full Article Now

You May Also Like

Journal of Drugs in Dermatology JDD Article About Assessing Patient Preferences for Atopic Dermatitis Treatment: A Review Article of Discrete Choice ExperimentsFeatured ArticlesThe Latest
October 8, 2024

Assessing Patient Preferences for Atopic Dermatitis Treatment: A Review Article of Discrete Choice Experiments

JDD Article Highlights Struggling with treatment adherence in your atopic dermatitis (AD) patients? AD is a widespread inflammatory skin condition, but even with various treatment options, poor adherence - especially to…
Journal of Drugs in Dermatology JDD article about Dermatologic Procedures for the Treatment of Seborrheic DermatitisFeatured ArticlesThe Latest
October 7, 2024

Dermatologic Procedures for the Treatment of Seborrheic Dermatitis

Did You Miss It? Published early online in August, the JDD article titled “Dermatologic Procedures for the Treatment of Seborrheic Dermatitis” reviews alternative dermatologic procedures for treating Seborrheic Dermatitis (SD), offering clinicians…
Journal of Drugs in Dermatology JDD article titled The ABCs of JAKis: A Clinician's Guide to Safety and Monitoring of the Systemic JAK InhibitorsFeatured ArticlesThe Latest
October 2, 2024

The ABCs of JAKis: A Clinician’s Guide to Safety and Monitoring of the Systemic JAK Inhibitors

JDD Article Highlight Curious about the latest in dermatology treatments? Janus Kinase Inhibitors (JAKis) are gaining traction as a powerful tool for various skin conditions—but there’s more to the story.…

Leave a Reply